Read the Journal of Managed Care + Specialty Pharmacy (JMCP) May 2025 Issue
AMCP Joins 50 Other Organizations in Support of the Reintroduction of the CREATES Act
We, the undersigned, commend you for your leadership, commitment to reducing out-of-control prescription drug prices, and efforts to stop anti-competitive abuses that keep drug prices high for patients. We were encouraged by the Senate Judiciary Committee’s bipartisan approval of the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974) last Congress. On the reintroduction of this legislation in the 116th session of Congress, we again pledge our support for the CREATES Act and look forward to continuing to work with you to get this bill across the finish line this year.
Related
AMCP is your partner in navigating AI’s transformative potential—ensuring patient-centered, ethically sound, and strategically aligned implementation across pharmacy practice and policy.
Retinal diseases in patients with diabetes pose signi cant challenges for health care systems. With a high treatment burden and advances in durable therapies, managed care organizations can optimize patient care by addressing coverage barriers that impact timely treatment with anti-VEGF therapies. This roadmap outlines essential points to better retinal disease management and improve treatment for populations of patients with diabetes at high risk for blindness.
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
